Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AASUR: ARN-509+Abiraterone+Leuprolide With Radiation in High Risk Prostate Cancer
NCT02772588Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2016
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants With Biochemical Failure at 36 months. Started May 2016; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02772588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772588.